Henry B. Lowman

Overview

Best Publications

• Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber

  Henner Dennis J;Wells James A;Lowman Henry B;Matthews David J

  2030
  Citations

• Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

  Jagath R Junutula;Helga Raab;Suzanna Clark;Sunil Bhakta

  1433
  Citations

• Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.

  Y. Chen;C. Wiesmann;G. Fuh;Bing Li

  1230
  Citations

• Immunoglobulin variants and uses thereof

  Camellia W. Adams;Andrew C. Chan;Craig W. Crowley;Henry B. Lowman

  1066
  Citations

• Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.

  Napoleone Ferrara;Lisa Damico;Naveed Shams;Henry Lowman

  1061
  Citations

• FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family

  Ilona N. Holcomb;Rhona C. Kabakoff;Betty Chan;Thad W. Baker

  928
  Citations

• Cysteine engineered antibodies and conjugates

  Charles W. Eigenbrot;Jagath Reddy Junutula;Henry Lowman;Helga E. Raab

  728
  Citations

• Selecting high-affinity binding proteins by monovalent phage display.

  Henry B. Lowman;Steven H. Bass;Nancy Simpson;James A. Wells

  633
  Citations

• Anti-VEGF antibodies

  Manuel Baca;James A. Wells;Leonard G. Presta;Henry B. Lowman

  620
  Citations

• Phage display for selection of novel binding peptides.

  Sachdev S. Sidhu;Henry B. Lowman;Brian C. Cunningham;James A. Wells

  614
  Citations

• VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface.

  Yves A Muller;Yvonne Chen;Hans W Christinger;Bing Li

  386
  Citations

• BACTERIOPHAGE DISPLAY AND DISCOVERY OF PEPTIDE LEADS FOR DRUG DEVELOPMENT

  Lowman Hb

  335
  Citations

• Affinity Maturation of Human Growth Hormone by Monovalent Phage Display

  Henry B. Lowman;James A. Wells

  327
  Citations

• Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.

  Yik Andy Yeung;Maya K. Leabman;Jonathan S. Marvin;Julia Qiu

  317
  Citations

• Methods and compositions for prolonging elimination half-times of bioactive compounds

  Warren L. Delano;Mark S. Dennis;Henry B. Lowman

  293
  Citations

• Serum albumin binding peptides for tumor targeting

  Mark S. Dennis;Henry B. Lowman;Warren L. Delano

  261
  Citations

• Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index.

  Luc R. Desnoyers;Olga Vasiljeva;Jennifer H. Richardson;Annie Yang

  261
  Citations

• Interaction between bevacizumab and murine VEGF-A: a reassessment.

  Lanlan Yu;Xiumin Wu;Zhiyong Cheng;Chingwei V Lee

  253
  Citations

• Anti-IgE antibodies and method of improving polypeptides

  Henry B. Lowman;Leonard G. Presta;Paula M. Jardieu;John Lowe

  239
  Citations

• Human growth hormone variants

  Brian C. Cunningham;Henry B. Lowman;James A. Wells;Ross G. Clark

  238
  Citations